Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy (PROMETEO II)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04130152 |
|
Recruitment Status :
Completed
First Posted : October 17, 2019
Last Update Posted : October 25, 2022
|
Sponsor:
SOLTI Breast Cancer Research Group
Collaborator:
Pfizer
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | January 26, 2022 |
| Actual Study Completion Date : | February 24, 2022 |